Drugs / 18F-JNJ-64413739
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03437590 | Mar → Oct 2018 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT03088644 | Mar → Nov 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]-JNJ-64413739 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03437590 ↗ |
| Known as | JNJ-64413739 F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068778 ↗ |
| Modality | Diagnostic / imaging agent | “the Newly Developed P2X7 Receptor PET Tracer 18F-JNJ-64413739” NCT03088644 ↗ |
| Route | Intravenous | “18F-JNJ-64413739 fluid for injection administered intravenously.” NCT03088644 ↗ |